GSK2190915 30mg

DRUG2 trials

Sponsors

GlaxoSmithKline

Conditions

Asthma

Phase 1

A Repeat Dose Study to Investigate the Interaction of GSK2190915 on the Pharmacokinetics of Rosuvastatin

CompletedNCT01411111

GlaxoSmithKlineAsthma

Start: 2011-01-06End: 2011-02-23Updated: 2017-07-25

Phase 2

Dose Ranging Study Evaluating the Efficacy and Safety of GSK2190915 Administered Once Daily

CompletedNCT01147744

GlaxoSmithKlineAsthma

Start: 2010-06-28End: 2011-10-06Updated: 2017-10-02

Related Papers

Efficacy, safety and tolerability of GSK2190915, a 5-lipoxygenase activating protein inhibitor, in adults and adolescents with persistent asthma: a randomised dose-ranging study.

2013-05-1723 citations